AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15930452 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra-containing diet with daily multivitamin (Centrum)
Number of subjects: 37
Study 15930452 — intervention group
Group type: COMPARATOR
Intervention: Control diet (33% energy from fat)
Number of subjects: 37
Study 15930452 — intervention group
Group type: COMPARATOR
Intervention: Fat-reduced diet (25% of energy from fat)
Number of subjects: 37
Study 12875315 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic cyclists
Number of subjects: 24
Study 12875315 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic cyclists
Number of subjects: 24
Study 10226125 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscopic ovarian coagulation
Number of subjects: 18
Study 10226125 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic ovarian coagulation
Number of subjects: 18
Study 8967669 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated alteplase therapy
Number of subjects: 41021
Study 8967669 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 41021
Study 1725890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim 1 mg
Number of subjects: 8
Study 1725890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromakalim 2 mg
Number of subjects: 8
Study 1725890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6091484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g single dose)
Number of subjects: 104
Study 6091484 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (seven doses)
Number of subjects: 104
Study 30733268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 56
Study 30733268 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 56
Study 29633339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal acetic acid infusion (50 mL)
Number of subjects: 210
Study 29633339 — intervention group
Group type: COMPARATOR
Intervention: Saline (50 mL)
Number of subjects: 210
Study 26791556 — intervention group
Group type: EXPERIMENTAL
Intervention: Infancy iron supplementation (∼1 mg Fe/(kg · d) as oral iron proteinsuccynilate)
Number of subjects: 1276
Study 24858737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power fractional CO2 laser
Number of subjects: 40
Study 24858737 — intervention group
Group type: COMPARATOR
Intervention: Low-fluence Q-switch 1,064 nm Nd:YAG laser
Number of subjects: 40
Study 23217054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 429
Study 23217054 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training
Number of subjects: 429
Study 23217054 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control (Seated Stretching Exercise)
Number of subjects: 429
Study 23217054 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Leg Strength
Number of subjects: 429
Study 23217054 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural Stability
Number of subjects: 429
Study 23217054 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Function
Number of subjects: 429
Study 20350920 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment (50 to 100 mcg daily)
Number of subjects: 0
Study 20350920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17545843 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m2 on days 1 and 8, every 21 days for three cycles, followed by Docetaxel 35 mg/m2 on days 1, 8, and 15, every 28 days for three cycles (S0027)
Number of subjects: 228
Study 17545843 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 30 mg/m2 on days 1, 8, and 15, every 28 days, or 75 mg/m2 every 21 days (LUN 6)
Number of subjects: 228
Study 17545843 — intervention group
Group type: COMPARATOR
Intervention: N/A (under-80 cohort from S0027 as control)
Number of subjects: 228
Study 17545843 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (80-and-older group)
Number of subjects: 228
Study 17545843 — intervention group
Group type: COMPARATOR
Intervention: N/A (under-80 group)
Number of subjects: 228
Study 17524571 — intervention group
Group type: COMPARATOR
Intervention: 50 Gy Whole-Breast Irradiation (WBI)
Number of subjects: 258
Study 17524571 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 x 5.2 Gy High-Dose-Rate Brachytherapy (HDR-BT)
Number of subjects: 258
Study 17524571 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy Electron Irradiation (ELE)
Number of subjects: 258
Study 15500893 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (22 microg)
Number of subjects: 263
Study 15500893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 11526363 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg once daily for 24 weeks
Number of subjects: 322
Study 11526363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 9290854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa with comorbid alcohol dependence
Number of subjects: 114
Study 9290854 — intervention group
Group type: COMPARATOR
Intervention: Bulimia nervosa without alcohol dependence
Number of subjects: 114
Study 8322247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of terbutaline nebuliser solution
Number of subjects: 21
Study 3575033 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-predominant formula (ratio of whey proteins to caseins of 60:40)
Number of subjects: 0
Study 3575033 — intervention group
Group type: COMPARATOR
Intervention: Casein-predominant formula (ratio of whey proteins to caseins of 18:82)
Number of subjects: 0
Study 3575033 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-predominant formula
Number of subjects: 0
Study 3575033 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulas
Number of subjects: 0
Study 31917054 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage periarticular injection (injection just before arthrotomy)
Number of subjects: 140
Study 31917054 — intervention group
Group type: COMPARATOR
Intervention: Late-stage periarticular injection (placebo before arthrotomy, injection after implantation)
Number of subjects: 140
Study 31160295 — intervention group
Group type: EXPERIMENTAL
Intervention: IV methotrexate (MTX)
Number of subjects: 44
Study 31160295 — intervention group
Group type: COMPARATOR
Intervention: Oral (PO) methotrexate (MTX)
Number of subjects: 44
Study 28399112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus Nordic FLOX (continuous or intermittent fluorouracil, folinic acid, and oxaliplatin)
Number of subjects: 566
Study 28399112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy
Number of subjects: 566
Study 28399112 — intervention group
Group type: COMPARATOR
Intervention: Nordic FLOX alone
Number of subjects: 566
Study 26079800 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal catheter (3-day ropivacaine 0.2% infusion)
Number of subjects: 80
Study 26079800 — intervention group
Group type: COMPARATOR
Intervention: Femoral catheter (3-day ropivacaine 0.2% infusion)
Number of subjects: 80
Study 23500537 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol margarine
Number of subjects: 43
Study 23500537 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol margarine
Number of subjects: 43
Study 23500537 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 43
Study 23500537 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 43
Study 21198901 — intervention group
Group type: EXPERIMENTAL
Intervention: modSLA implants
Number of subjects: 22
Study 21198901 — intervention group
Group type: COMPARATOR
Intervention: SLA implants
Number of subjects: 22
Study 19216016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline, 400 mg twice daily
Number of subjects: 40
Study 19216016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19216016 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline and Placebo
Number of subjects: 40
Study 16769831 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 243
Study 15111342 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU 200 mg/m² daily continuous infusion for 18 weeks with epirubicin 60 mg/m² and cisplatin 60 mg/m² (infusional ECisF)
Number of subjects: 426
Study 15111342 — intervention group
Group type: COMPARATOR
Intervention: Conventional bolus doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC)
Number of subjects: 426
Study 11574128 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 241
Study 11574128 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 241
Study 9855373 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry measurement
Number of subjects: 15
Study 9855373 — intervention group
Group type: COMPARATOR
Intervention: No indirect calorimetry measurement
Number of subjects: 15
Study 7864679 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study 7864679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder carcinoma patients
Number of subjects: 50
Study 7864679 — intervention group
Group type: EXPERIMENTAL
Intervention: Undifferentiated tumors (Broders' classification 1, 2, 3, and 4)
Number of subjects: 50
Study 2592090 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to hospital for 24 hours
Number of subjects: 114
Study 2592090 — intervention group
Group type: COMPARATOR
Intervention: Discharge from the accident department
Number of subjects: 114
Study 31738014 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 301
Study 31738014 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 301
Study 31738014 — intervention group
Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 301
Study 31286731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with grain‐moxibustion
Number of subjects: 60
Study 31286731 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study 28254231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical ripening balloon (CRB) group with double‐balloon catheter (COOK CRB), inflated with 30‐80 mL of normal saline for 12 hours
Number of subjects: 167
Study 28254231 — intervention group
Group type: COMPARATOR
Intervention: Non-CRB group (vaginal and oral misoprostol alone)
Number of subjects: 167
Study 26429398 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 646
Study 26429398 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 646
Study 22946635 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt containing Lactobacillus rhamnosus GG (LGG) and fructooligosaccharide (FOS) Actilight(®) administered daily for 4 weeks
Number of subjects: 0
Study 21658884 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 1% lidocaine
Number of subjects: 120
Study 21658884 — intervention group
Group type: COMPARATOR
Intervention: 2 mL of 0.9% NaCl
Number of subjects: 120
Study 21658884 — intervention group
Group type: COMPARATOR
Intervention: No infiltration
Number of subjects: 120
Study 19366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg twice daily for 7 days, followed by 15 mg twice daily if no visual symptoms reported
Number of subjects: 90
Study 19366275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16686575 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability Ball Training (SBT)
Number of subjects: 20
Study 16686575 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 20
Study 15823773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine mesylate hemihydrate (17.3 mg oral dose)
Number of subjects: 16
Study 15823773 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine hydrochloride monohydrate (15 mg oral dose)
Number of subjects: 16
Study 11700399 — intervention group
Group type: EXPERIMENTAL
Intervention: rTFPI at 0.025 mg/kg/hr
Number of subjects: 210
Study 11700399 — intervention group
Group type: EXPERIMENTAL
Intervention: rTFPI at 0.05 mg/kg/hr
Number of subjects: 210
Study 11700399 — intervention group
Group type: EXPERIMENTAL
Intervention: rTFPI (both doses)
Number of subjects: 210
Study 11700399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 9404177 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane administered via a laryngeal mask airway (LMA)
Number of subjects: 40
Study 9404177 — intervention group
Group type: COMPARATOR
Intervention: Enflurane anaesthesia administered using a face mask
Number of subjects: 40
Study 8008999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 2961307 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of 5'-DFUR (800 mg/m2/day)
Number of subjects: 21
Study 2961307 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration of 5'-DFUR (1,400 mg/m2/day for 4 days followed by 3 days off)
Number of subjects: 21
Study 29455237 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 100
Study 29455237 — intervention group
Group type: COMPARATOR
Intervention: Water-based lubricant
Number of subjects: 100
Study 28804223 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 40
Study 28804223 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-reperfusion (I/R) group
Number of subjects: 40
Study 26469131 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led intervention (TL)
Number of subjects: 1707
Study 26469131 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-led intervention (RL)
Number of subjects: 1707
Study 26469131 — intervention group
Group type: COMPARATOR
Intervention: Control group (lessons as usual)
Number of subjects: 1707
Study 22759198 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 0.5-2.5 mg as solution or 5-50 mg as tablets
Number of subjects: 64
Study 22759198 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg
Number of subjects: 64
Study 22759198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 20842166 — intervention group
Group type: EXPERIMENTAL
Intervention: [(57)Fe]-ferrous fumarate
Number of subjects: 3
Study 20842166 — intervention group
Group type: COMPARATOR
Intervention: [(58)Fe]-ferrous sulfate
Number of subjects: 3
Study 18332775 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat chair intervention
Number of subjects: 293
Study 18332775 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved chair intervention
Number of subjects: 293
Study 18332775 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo intervention)
Number of subjects: 293
Study 17154734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 56
Study 17154734 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 56
Study 14719426 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 10 mg in 5 ml saline with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 1)
Number of subjects: 50
Study 14719426 — intervention group
Group type: COMPARATOR
Intervention: 5 ml saline (placebo control) with prilocaine 1% 10 ml and lignocaine 2% 20 ml with adrenaline 1:200,000 (Group 2)
Number of subjects: 50
Study 10840426 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 340
Study 10840426 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection
Number of subjects: 340
Study 10840426 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 340
Study 9386847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 0
Study 9386847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8197031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate 7.5 mg with acetaminophen 500 mg
Number of subjects: 232
Study 8197031 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate 30 mg with acetaminophen 300 mg
Number of subjects: 232
Study 8197031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 3147522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg twice daily for 1 week)
Number of subjects: 114
Study 3147522 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 1 week)
Number of subjects: 114
Study 31346609 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 150
Study 31346609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing injection drug use (IDU)
Number of subjects: 150
Study 31346609 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting ongoing IDU
Number of subjects: 150
Study 31329983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 30 IU/kg (VE30)
Number of subjects: 80
Study 31329983 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella Enteritidis (SE)
Number of subjects: 80
Study 31329983 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (PS)
Number of subjects: 80
Study 29137041 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 144
Study 29137041 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 144
Study 26169935 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine alone
Number of subjects: 9
Study 26169935 — intervention group
Group type: EXPERIMENTAL
Intervention: EAAs with leucine
Number of subjects: 9
Study 26169935 — intervention group
Group type: EXPERIMENTAL
Intervention: EAAs
Number of subjects: 9
Study 26169935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored water)
Number of subjects: 9
Study 23354314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild water‐filtered near infrared whole body hyperthermia once a week
Number of subjects: 67
Study 23354314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild water‐filtered near infrared whole body hyperthermia twice a week
Number of subjects: 67
Study 23354314 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal rehabilitation
Number of subjects: 67
Study 21700419 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 21700419 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated condition
Number of subjects: 0
Study 18469732 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli Nissle 1917 (EcN) suspension (1-3 mL daily for 21 days)
Number of subjects: 151
Study 16556690 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (INH)
Number of subjects: 226
Study 16556690 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (SC)
Number of subjects: 226
Study 12545256 — intervention group
Group type: EXPERIMENTAL
Intervention: Open craniotomy and resection of the tumour
Number of subjects: 30
Study 12545256 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic biopsy
Number of subjects: 30
Study 12545256 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (amount given)
Number of subjects: 30
Study 12545256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Open craniotomy and Stereotactic biopsy)
Number of subjects: 30
Study 14629844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture in addition to standard care (n = 11)
Number of subjects: 41
Study 14629844 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure and standard care (n = 17)
Number of subjects: 41
Study 14629844 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (n = 13)
Number of subjects: 41
Study 10637151 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA-seropositive men
Number of subjects: 129
Study 10637151 — intervention group
Group type: COMPARATOR
Intervention: IgA-seronegative men
Number of subjects: 129
Study 8727434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine infusion (2 micrograms.kg-1.min-1) during 2-hour periods
Number of subjects: 29
Study 8727434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine infusion (2 micrograms.kg-1.min-1) after 48 hours
Number of subjects: 29
Study 8727434 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dopamine infusion (2 micrograms.kg-1.min-1)
Number of subjects: 29
Study 1888820 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg fluconazole daily for 14‐28 days
Number of subjects: 16
Study 1888820 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg fluconazole weekly for 6 months
Number of subjects: 16
Study 1888820 — intervention group
Group type: COMPARATOR
Intervention: Placebo weekly for 6 months
Number of subjects: 16
Study 6384850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (2 g, 12 doses)
Number of subjects: 70
Study 6384850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6384850 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 70
Study 3532966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg daily for two months)
Number of subjects: 36
Study 3532966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31652561 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperbaBoostTM krill oil
Number of subjects: 0
Study 31652561 — intervention group
Group type: COMPARATOR
Intervention: Choline bitartrate
Number of subjects: 0
Study 29231607 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of regular acupuncture and contralateral needling technique at distal acupoints
Number of subjects: 60
Study 29231607 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture
Number of subjects: 60
Study 26383189 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 120
Study 26383189 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser tonsillectomy
Number of subjects: 120
Study 26383189 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 120
Study 23550665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy Japanese version (CST-J), 14 sessions, twice a week for 7 weeks
Number of subjects: 56